Zhou Jian, Fan Jia, Wu Zhi-quan, Qiu Shuang-jian, Wang Zheng, Huang Xiao-wu, Yu Yao, He Yi-feng, Tang Zhao-you, Wang Yu-qi
Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Zhonghua Yi Xue Za Zhi. 2005 Jul 13;85(26):1805-8.
To investigate the measures to further improve the therapeutic efficacy of liver transplantation.
The clinical data of 203 consecutive cases of orthotopic liver transplantation (OLT) performed in Zhongshan Hospital, Fudan University April 2001 to October 2004, with the indications for considering OLT of hepatocellular carcinoma (HCC) (142 cases), liver cirrhosis (36 cases), fulminant hepatic failure (7 cases), Wilson's disease (6 cases), and other end-stage liver diseases (12 cases), including 199 cases of cadaveric OLT, inclusive of 2 cases of reduced-size and 1 case of splitting liver transplantation, and 4 cases of living-donor liver transplantation, were retrospectively analyzed. Multivariate analysis using Cox proportional hazards regression model was applied to determine the risk factors predicting liver transplantation prognosis for HCC.
For the whole group of the 201 patients, the 1-year and 2-year cumulative survival rates were 85.0% and 82.4% respectively and the rejection rate was 12.3%. In the HCC group the 1- and 2-year cumulative survival rates were 80.2% and 78.4%, and the 1- and 2-year disease-free survival (DFS) rates were 85.3% and 80.3% respectively. HCC recurrence was observed in 20 patients after OLT with a recurrence rate of 14.1%. Multivariate analysis revealed that the tumor size and portal vein tumor thrombus were the most independent and statistically significant factors affecting the DFS.
OLT may be the most effective treatment option for patients with end-stage liver diseases and may also provide the opportunity of curative treatment or survival improvement for selected patients with hepatic malignancies.
探讨进一步提高肝移植治疗效果的措施。
回顾性分析2001年4月至2004年10月在复旦大学附属中山医院连续进行的203例原位肝移植(OLT)患者的临床资料,其中肝细胞癌(HCC)(142例)、肝硬化(36例)、暴发性肝衰竭(7例)、威尔逊病(6例)及其他终末期肝病(12例)符合OLT适应证,包括199例尸体供肝OLT,其中2例为减体积肝移植,1例为劈离式肝移植,4例为活体供肝肝移植。采用Cox比例风险回归模型进行多因素分析,以确定预测HCC肝移植预后的危险因素。
201例患者的全组1年和2年累积生存率分别为85.0%和82.4%,排斥反应率为12.3%。HCC组1年和2年累积生存率分别为80.2%和78.4%,1年和2年无病生存率(DFS)分别为85.3%和80.3%。OLT术后20例患者出现HCC复发,复发率为14.1%。多因素分析显示,肿瘤大小和门静脉癌栓是影响DFS最独立且具有统计学意义的因素。
OLT可能是终末期肝病患者最有效的治疗选择,也可能为部分肝恶性肿瘤患者提供治愈性治疗或改善生存的机会。